Brevan Howard Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Brevan Howard Capital Management’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.03M	Buy	13,718 +9,843	+254%	+$2.79M	0.03%	430
2026 Q1	$1.08M	Buy	+3,875	New	+$1.12M	0.01%	858
2025 Q4	–	Sell	-5,592	Closed	-$1.57M	–	1816
2025 Q3	$1.57M	Sell	5,592 -16,222	-74%	-$4.41M	0.01%	678
2025 Q2	$5.26M	Buy	+21,814	New	+$5.16M	0.03%	353
2024 Q4	–	Sell	-11,083	Closed	-$3.71M	–	1056
2024 Q3	$3.71M	Buy	11,083 +8,825	+391%	+$2.8M	0.03%	162
2024 Q2	$617K	Buy	2,258 +1,403	+164%	+$408K	0.01%	535
2024 Q1	$296K	Sell	855 -552	-39%	-$182K	﹤0.01%	662
2023 Q4	$454K	Buy	+1,407	New	+$441K	0.01%	523

Other funds holding BIO

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Brevan Howard Capital Management's BIO Position: Q2 2026 in Review

Brevan Howard Capital Management increased its Bio-Rad Laboratories Class A (BIO) stake by 254% in Q2 2026, buying an estimated $2.79M and bringing the position to 13,718 shares worth $4.03M. The position accounts for 0.03% of the portfolio, ranked #430.

Brevan Howard Capital Management first reported a position in BIO in Q4 2023 and has held it in 8 quarters since. The position peaked at $5.26M in Q2 2025. 400 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

Brevan Howard Capital Management held 13,718 shares of Bio-Rad Laboratories Class A worth $4.03M as of Q2 2026.
Brevan Howard Capital Management bought 9,843 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $2.79M.
Bio-Rad Laboratories Class A made up 0.03% of Brevan Howard Capital Management's portfolio in Q2 2026, its #430 holding.
Brevan Howard Capital Management first reported a position in Bio-Rad Laboratories Class A in Q4 2023 and has held it in 8 quarters since.
Brevan Howard Capital Management's Bio-Rad Laboratories Class A position peaked at $5.26M in Q2 2025.
400 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.